These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. IDH-mutant gliomas with additional class-defining molecular events. Ahrendsen JT; Torre M; Meredith DM; Hornick JL; Reardon DA; Wen PY; Yeo KK; Malinowski S; Ligon KL; Ramkissoon S; Alexandrescu S Mod Pathol; 2021 Jul; 34(7):1236-1244. PubMed ID: 33772213 [TBL] [Abstract][Full Text] [Related]
26. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180 [TBL] [Abstract][Full Text] [Related]
27. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing. Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617 [TBL] [Abstract][Full Text] [Related]
28. Adult IDH wild-type lower-grade gliomas should be further stratified. Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485 [TBL] [Abstract][Full Text] [Related]
29. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients. Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941 [TBL] [Abstract][Full Text] [Related]
30. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas. Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259 [TBL] [Abstract][Full Text] [Related]
31. Characteristics of gliomas in patients with somatic IDH mosaicism. Bonnet C; Thomas L; Psimaras D; Bielle F; Vauléon E; Loiseau H; Cartalat-Carel S; Meyronet D; Dehais C; Honnorat J; Sanson M; Ducray F Acta Neuropathol Commun; 2016 Mar; 4():31. PubMed ID: 27036230 [TBL] [Abstract][Full Text] [Related]
32. Determining optimal treatment strategy for diffuse glioma: the emerging role of IDH mutations. Juratli TA; Cahill DP; McCutcheon IE Expert Rev Anticancer Ther; 2015 Jun; 15(6):603-6. PubMed ID: 25980633 [TBL] [Abstract][Full Text] [Related]
33. Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. Komori T Lab Invest; 2022 Feb; 102(2):126-133. PubMed ID: 34504304 [TBL] [Abstract][Full Text] [Related]
34. IDH1 and IDH2 mutations in gliomas. Cohen AL; Holmen SL; Colman H Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369 [TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations. Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of MTAP and p16 immunohistochemical deficiency as surrogate marker for CDKN2A/B homozygous deletion in gliomas. Maragkou T; Reinhard S; Jungo P; Pasquier B; Neuenschwander M; Schucht P; Vassella E; Hewer E Pathology; 2023 Jun; 55(4):466-477. PubMed ID: 37032198 [TBL] [Abstract][Full Text] [Related]
37. Pediatric-type high-grade gliomas with PDGFRA amplification in adult patients with Li-Fraumeni syndrome: clinical and molecular characterization of three cases. Kibe Y; Ohka F; Aoki K; Yamaguchi J; Motomura K; Ito E; Takeuchi K; Nagata Y; Ito S; Mizutani N; Shiba Y; Maeda S; Nishikawa T; Shimizu H; Saito R Acta Neuropathol Commun; 2024 Apr; 12(1):57. PubMed ID: 38605367 [TBL] [Abstract][Full Text] [Related]
38. 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas. Zhang Y; Xie Y; He L; Tang J; He Q; Cao Q; Cui L; Guo W; Hua K; Dimberg A; Wang L; Zhang L Cell Oncol (Dordr); 2021 Feb; 44(1):193-204. PubMed ID: 32915415 [TBL] [Abstract][Full Text] [Related]
39. Therapies for IDH-Mutant Gliomas. Alshiekh Nasany R; de la Fuente MI Curr Neurol Neurosci Rep; 2023 May; 23(5):225-233. PubMed ID: 37060388 [TBL] [Abstract][Full Text] [Related]
40. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]